Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
– Family Health History Road Trip Program Aims to Inspire Conversations About Health History and Empower Families to Take Control of Their Health –
– Genealogist and Health Educator Bernice Bennett Travels Cross-Country to Visit Members of hATTR Amyloidosis Community and Highlight How Discussing Family Health History Can Drive Earlier Diagnosis –
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of the Family Health History Road Trip, its program designed to encourage conversations between family members about their health history so they can discuss with their doctor to better understand their risk for developing an inherited disease like hereditary ATTR (hATTR) amyloidosis. Inspired by the traditional family road trip, the program follows genealogist and health educator Bernice Bennett as she embarks on a cross-country road trip to meet with a physician expert in hATTR amyloidosis and affected families to learn more about the disease, hear patients’ journeys to diagnosis and explore how knowledge of family health history can drive an earlier diagnosis.
“When we speak about family history, we often focus on the stories about what country we came from, where family immigrated to, or what types of jobs or professions they held; what we don’t tend to focus on is the health history of those who have walked before us,” said Bennett. “Family history is considered one of the most important risk factors for health problems. Knowing your family’s health history empowers you with important information to share with your doctor when seeking a diagnosis or determining your risk for developing an inherited disease like hATTR amyloidosis.”
myBinderRelated Content
-
Atrophic Nodular Cutaneous AmyloidosisPrimary cutaneous amyloidosis is limited...
-
AL Amyloidosis: Hot Topics From ISA 2020https://www.youtube.com/watch?v=n-41ooYJ...
-
Q&A Session 1 – ASG Webinar 4/13https://www.youtube.com/watch?v=NrEjyVeJ...
-
Muzaffar H. Qazilbash, MDMuzaffar Qazilbash is a Professor of med...
-
Liana (Brasil) – Convivendo com Amiloidose hATTRhttps://www.youtube.com/watch?v=S5N3Wj8_...
-
Natural History and Outcomes in Localised Immunoglobulin Light-Chain Amyloidosis: A Long-Term Observational StudyBackground: Localised immunoglobulin li...
-
Paul Cheng, MD, PhDDr. Cheng is a Cardiologist and Instru...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
